In a groundbreaking study recently published in BMC Cancer, researchers embarked on an ambitious quest to decode the selective vulnerabilities of ACC at an epigenetic level. This investigation deployed a comprehensive high-throughput screening platform, examining a vast library of 157 histone modifying drugs (HMDs) with the aim of targeting both bulk tumor cells and the elusive CSC populations. The study leveraged the UM-HACC-2A cell line, an established model of ACC, to distinguish the varied sensitivities between these two critical subpopulations in vitro.

The methodological approach was notable for its dual in vitro modeling system: conventional two-dimensional (2D) cultures designed to mimic the bulk, non-CSC tumor environment, and three-dimensional (3D) tumorspheres that enrich for CSCs. This design facilitated a nuanced understanding of how different classes of epigenetic inhibitors impact distinct cellular compartments within the tumor mass. Through the use of automated liquid handling and high-content imaging technologies—specifically, ImageXpress for image acquisition and MetaXpress for sophisticated image analysis—the team achieved a rigorous and reproducible quantification of cell viability and tumorsphere dynamics following drug exposure.

Results from this extensive screening revealed a fascinating divergence in drug efficacy between CSCs and non-CSCs. Fourteen candidate compounds emerged as potent inducers of apoptosis in the bulk tumor population, while eleven agents showed significant cytotoxic effects against tumorsphere-enriched CSCs. Key molecular targets identified among these hits spanned several histone modifying enzymes and associated epigenetic regulators, including histone deacetylases (HDACs), histone methyltransferases, EZH2, the c-RET kinase, and epidermal growth factor receptor (EGFR).

Particularly striking was the performance of ITF2357, also known as Givinostat, a histone deacetylase inhibitor that triggered an impressive 84% cell death in non-CSC populations, a level of efficacy that was highly statistically significant (p < 0.0001). In parallel, histone methyltransferase inhibitors UNC0631 and LLY-507 also demonstrated potent cytotoxicity in similar ranges (82.5% and 82.3% cell death, respectively), highlighting the promise of targeting methylation-modifying enzymes as a therapeutic strategy.

Conversely, in the CSC-enriched 3D tumorsphere model, where therapeutic resistance is most evident, the EZH2 inhibitor GSK343 exhibited notable activity, achieving 35.2% cell death with strong statistical significance. This differential response underscores the unique epigenetic landscapes and vulnerabilities present within cancer stem cells compared to their non-stem counterparts. The ability of EZH2 inhibition to impair tumorsphere viability suggests a critical role for histone methylation in CSC maintenance and survival.

Intriguingly, combination assays that paired effective agents identified separately against CSCs and non-CSCs unveiled synergistic interactions. These combinations substantially enhanced tumor cell death beyond what was observed with either drug alone, suggesting that a multipronged epigenetic therapy could overcome the heterogeneity and inherent resistance within ACC tumors. This combinatorial approach points toward personalized treatment regimens that concurrently disrupt multiple oncogenic pathways in both stem and bulk tumor compartments.

The implications of these findings stretch far beyond the immediate context of ACC. They offer compelling evidence that cancer stem cells and their differentiated progeny exhibit discrete epigenetic dependencies that require tailored therapeutic targeting. While epigenetic modulators have garnered attention across various malignancies, this study highlights their strategic utility against one of the most recalcitrant salivary gland cancers, providing a vital foothold in the pursuit of more effective therapies.

Not only does this research elevate our mechanistic understanding of ACC pathobiology, but it also lays the preclinical groundwork for advancing histone modifying drugs into clinical trials. The capacity to selectively eradicate CSCs, which drive metastatic spread and treatment resistance, alongside bulk tumor cells, may ultimately translate into improved patient outcomes and prolonged survival.

Moreover, this study exemplifies the power of integrating high-content screening with sophisticated in vitro models to dissect cellular heterogeneity and drug responsiveness at an unprecedented resolution. Such technical innovation paves the way for accelerated drug discovery and precision oncology strategies, especially for rare and poorly understood cancers like ACC.

Despite these promising advances, several questions remain open for exploration. The precise molecular mechanisms underpinning the differential sensitivity of CSCs versus non-CSCs to various histone modifiers need further elucidation. Additionally, validating these findings in in vivo ACC models and determining optimal dosing regimens and toxicity profiles will be critical steps toward clinical translation.

Furthermore, longitudinal studies tracking epigenetic changes during treatment could illuminate potential resistance pathways and identify biomarkers for therapy response. The integration of genomic and epigenomic data in ACC could deepen insights into tumor evolution and reveal new therapeutic targets.

In conclusion, this pioneering work by Emerick et al. opens a new chapter in the fight against adenoid cystic carcinoma by uncovering the selective impacts of histone modifying drugs on tumor subpopulations. It supports the growing paradigm that effective cancer therapies must address intratumoral complexity through combination regimens tailored to target both cancer stem cells and their differentiated progeny. As such, this research represents a beacon of hope, steering the oncology community closer to overcoming the therapeutic impasse posed by ACC and similar challenging malignancies.

Subject of Research: Selective impact of histone modifying drugs on adenoid cystic carcinoma bulk tumor cells and cancer stem cells.

Article Title: Assessing the selective impact of histone modifying drugs on adenoid cystic carcinoma cells and their stem cell counterparts.

Article References:
Emerick, C., Silva, L.C., Jang, Y. et al. Assessing the selective impact of histone modifying drugs on adenoid cystic carcinoma cells and their stem cell counterparts. BMC Cancer 25, 1277 (2025). https://doi.org/10.1186/s12885-025-14739-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14739-z

Traditional models of chemotherapy resistance often rely on prolonged drug exposure to cancer cell lines, ultimately resulting in artificial adaptations that only partially mirror patient tumors. In contrast, the organoids generated by Professor Toshiaki Ohteki’s team represent chemo-resistant ESCCs directly sourced from diverse patient specimens, maintaining essential oncogenic mutations and tumor microenvironmental characteristics. This patient-specific fidelity allows for more accurate evaluation of drug responses and molecular pathways driving resistance. The resulting organoid library encapsulates a spectrum of genetic backgrounds and clinical histories, reflecting the heterogeneity inherent in ESCC and offering a robust platform for personalized medicine approaches.

The study, published in Communications Biology, is the product of an extensive collaboration among researchers from the Institute of Science Tokyo’s Medical Research Laboratory, along with notable contributions from Keio University and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital. By cultivating organoids from 24 patients, the researchers confirmed that these miniaturized tumors retained hallmark ESCC features, including nuclear accumulation of the p53 protein, a common consequence of TP53 mutations which play a pivotal role in tumorigenesis. Genomic and transcriptomic analyses revealed that each organoid preserved patient-specific mutational landscapes and gene expression profiles linked to heightened proliferative capacity and DNA replication—key hallmarks of malignancy.

To evaluate the organoids’ physiological relevance, the team transplanted them into immunodeficient murine models, where the organoids recapitulated the histopathological architecture of the original tumors. The xenografts exhibited both morphological characteristics and molecular markers consistent with human ESCC, underscoring the organoids’ utility as faithful in vivo models. This dual validation—both in vitro and in vivo—offers a powerful tool for dissecting tumor biology, enabling researchers to interrogate resistance mechanisms and potential therapeutic interventions across multiple levels.

A central focus of the investigation was the response of the organoid lines to the standard chemotherapy regimen of cisplatin combined with 5-fluorouracil (CF), commonly employed in treating ESCC. While the majority of organoids displayed sensitivity to this treatment, a significant subset, approximately 29%, demonstrated inherent resistance. Intriguingly, these resistant organoids exhibited robust activation of the nuclear factor erythroid 2-related factor 2 (NRF2) pathway. This pathway orchestrates cellular defenses against oxidative stress by regulating antioxidant gene expression, but when aberrantly activated in cancer cells, NRF2 confers a survival advantage that blunts the efficacy of chemotherapy. Elevated expression of NRF2 downstream target genes such as ALDH3A1, SPP1, and TXNRD1 highlighted their potential role as biomarkers predictive of therapeutic resistance.

The identification of NRF2 pathway hyperactivity in chemo-resistant ESCC organoids aligns with emerging evidence implicating this signaling axis as a key modulator of tumor resilience. NRF2’s control over antioxidant response elements enables malignant cells to offset the oxidative damage inflicted by chemotherapeutic agents, contributing to treatment failure. Recognizing this, the research not only advances understanding of resistance biology but also underscores the necessity for precision medicine strategies that incorporate biomarker-guided patient stratification, enabling clinicians to tailor therapeutic regimens consonant with tumor-specific molecular profiles.

Despite the protective shield provided by NRF2 activation, the researchers serendipitously discovered that the drug fedratinib, originally developed as a Janus kinase 2 (JAK2) inhibitor for myeloproliferative disorders, exerted superior antitumor effects against resistant ESCC organoids compared to standard CF therapy. Remarkably, this efficacy appeared independent of the NRF2 pathway, suggesting alternative mechanisms at play. Subsequent investigations revealed that fedratinib’s anti-proliferative properties are linked to the inhibition of bromodomain-containing protein 4 (BRD4), a chromatin reader implicated in regulating transcriptional programs essential for cancer cell growth and survival. By repressing BRD4 function, fedratinib disrupts oncogenic transcriptional networks, representing a promising therapeutic avenue capable of bypassing NRF2-mediated resistance.

The deployment of patient-derived organoids as a preclinical testing platform exemplifies the translational power of this technology. Beyond modeling cancer heterogeneity, organoids permit high-throughput drug screening and mechanistic studies within a physiologically relevant context, accelerating the identification of novel treatments and combination strategies. This paradigm shift from traditional cell line models towards patient-specific organoids heralds a new era in oncology research, where therapeutic decisions can be informed by direct functional assessment of tumor responses, enhancing treatment precision and efficacy.

Professor Ohteki emphasizes that the ESCC organoid library’s breadth—encompassing multiple chemo-resistant clones with diverse oncogenic mutations—provides an invaluable resource for probing differential drug susceptibilities and resistance pathways. As approximately 28% of ESCC patients exhibit suboptimal responses to neoadjuvant chemotherapy, the availability of such predictive biomarkers and organoid models is critical for early identification of patients unlikely to benefit from standard protocols. This will facilitate timely transition to alternative therapies, potentially improving survival outcomes and quality of life.

The research heralds significant clinical implications, notably the prospect of personalizing ESCC treatment regimens based on organoid-based sensitivity profiling and biomarker expression, such as NRF2 targets and BRD4 activity. Moreover, the successful repurposing of fedratinib underscores how existing drugs can be redirected to combat chemotherapy-resistant malignancies, potentially shortening the timeline to clinical application. Future investigations are poised to extend these findings, exploring combination therapies that may overcome multifaceted resistance mechanisms and investigating the role of tumor microenvironmental factors within organoid systems.

The Institute of Science Tokyo, newly formed through the merger of the Tokyo Medical and Dental University and Tokyo Institute of Technology, reinforces its mission to advance scientific discovery and translate research into societal value through this pioneering study. By integrating multidisciplinary expertise and leveraging innovative technologies, the institute contributes to combating one of the most challenging cancers, offering renewed hope for patients afflicted with ESCC.

In conclusion, the development of a patient-derived ESCC organoid library has illuminated critical pathways underpinning chemotherapy resistance while providing a versatile platform for preclinical drug evaluation. This work exemplifies the potential for organoid technology to transform cancer research, enabling precision oncology to move from concept to clinical reality. As these findings propagate through the medical community, they promise to stimulate further research and accelerate the development of effective, personalized therapies that address the urgent unmet needs in esophageal cancer treatment.

Subject of Research: Cells

Article Title: An organoid library of human esophageal squamous cell carcinomas (ESCCs) uncovers the chemotherapy-resistant ESCC features

News Publication Date: 1-Apr-2025

Web References:
DOI: 10.1038/s42003-025-07869-4

Image Credits: Institute of Science Tokyo

Keywords: Esophageal cancer, Diseases and disorders, Cancer, Carcinoma, Medical treatments